Vyriad, a company focused on developing targeted genetic therapies, has secured $25.0 million in new investment capital from investors. This funding round will support the company's ongoing efforts to advance its innovative approach to treating various diseases, particularly in oncology.
The company specializes in engineering viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to targeted cells. This core technology facilitates oncolytic virotherapy, in vivo gene therapies, and gene editing applications. Vyriad is actively testing its oncolytic viruses both as monotherapies and in combination with immuno-oncology drugs. Its Phase 1-2 clinical studies are currently active across several cancer types, including non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, breast cancer, and bladder cancer. Vyriad also maintains clinical research collaboration agreements with institutions such as Regeneron and Mayo Clinic.
This capital infusion is significant for Vyriad as it continues to progress its pipeline of genetic therapies. The funds are expected to be deployed towards accelerating research and development initiatives, supporting the expansion of its clinical programs, and strengthening its operational capabilities. The investment underscores confidence in Vyriad's platform and its potential to address unmet medical needs through its targeted therapeutic strategies.
Looking ahead, Vyriad plans to leverage this funding to further its mission of bringing next-generation genetic therapies to patients. The company remains committed to advancing its clinical trials and exploring new applications for its viral engineering technology, aiming to broaden its impact in the field of precision medicine.
